Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy.
about
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophyAttempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle.Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.Myogenin regulates exercise capacity but is dispensable for skeletal muscle regeneration in adult mdx mice.Neuronal nitric oxide synthase-rescue of dystrophin/utrophin double knockout mice does not require nNOS localization to the cell membraneCo-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation.Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP.Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.Measuring mitochondrial respiration in intact single muscle fibers.Differential calmodulin-modulatory and electron transfer properties of neuronal nitric oxide synthase mu compared to the alpha variant.Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy.Dystrophin induced cognitive impairment: mechanisms, models and therapeutic strategiesMicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients.nNOS regulation of skeletal muscle fatigue and exercise performance.Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.Age-dependent neuromuscular impairment in prion protein knockout mice.Phosphofructokinase-1 Negatively Regulates Neurogenesis from Neural Stem Cells.Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders.Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice.Macrophages escape Klotho gene silencing in the mdx mouse model of Duchenne muscular dystrophy and promote muscle growth and increase satellite cell numbers through a Klotho-mediated pathway.Exercise-induced angiogenesis correlates with the up-regulated expression of neuronal nitric oxide synthase (nNOS) in human skeletal muscle.Splitting of Pi and other ³¹P NMR anomalies of skeletal muscle metabolites in canine muscular dystrophy.Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice.Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies.
P2860
Q24630041-14519A13-BDFD-4288-8288-D0D3FF18142CQ33586004-14B302DA-3EB4-43FE-9EE2-B6FB089949EAQ33599468-EABC523E-9727-4B34-9D3E-792450FFABAAQ33802635-3B706C77-63B8-4659-A792-5DBD0EAFBAE2Q34049251-AD82267F-E89F-4BC6-8BD3-F2AF65D2B8F6Q34124872-8B235E43-9353-4E13-9D94-6189AC1B1186Q34748781-9CF86265-8118-46D7-A668-88732ECC0844Q34764061-5BF36704-1029-48DE-8DE8-D9678DF26C1FQ35986842-D3C1D48B-BD5B-423C-8040-9D77946B3F8BQ36043923-FC720609-89E5-4970-AFED-2C3D2A7C1DF3Q36422465-C4225A7F-F1EE-44E6-A4CE-4F51C58516F1Q37175483-F20F3F24-77AD-411C-BA45-F8F5094D608CQ37498495-152C125F-B97E-4858-860B-2960D4A65F3CQ37893076-4B81F58E-401A-4CDE-A4D8-C2BAD1F75DB8Q38246459-FA388553-729A-4172-AA7F-16271F4903C9Q38541264-D1649910-C2E2-4EA6-9F12-008FF3FCF499Q39178174-A332E8CD-4EAB-4457-83B8-FCDA68575F79Q39310461-0AB09656-98F3-42F7-9027-3B4EFCB2E0C5Q39330717-B7B097A1-D96F-4DCC-9912-ED4E3AF48B5CQ41031903-DFEB30DF-1242-4449-81FF-D25B642F63BDQ41217812-D5D9BD6A-6540-4A01-83EB-B84145A72C46Q41465861-B7C3C44F-4F21-4471-A706-72786A8EC15DQ42697846-7053C67A-AFE0-46FD-85D4-CEDC6792B3BFQ43884201-FA1DDAE0-B396-422B-A35A-AECA007D998BQ46439994-BBE19875-47F9-4209-B261-069246A00A2CQ51577358-FE6DFB5D-9086-4CE7-AC7D-EE1DF3E1850AQ52621969-92FE9EA5-2A82-4DD1-AAD8-3F4193345721Q52920061-32BC53DA-77DD-4085-83D6-D3B42FC3977CQ55515149-1D863500-6020-41FE-96F4-D65FA16F1157
P2860
Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Loss of positive allosteric in ...... ability in muscular dystrophy.
@en
Loss of positive allosteric in ...... ability in muscular dystrophy.
@nl
type
label
Loss of positive allosteric in ...... ability in muscular dystrophy.
@en
Loss of positive allosteric in ...... ability in muscular dystrophy.
@nl
prefLabel
Loss of positive allosteric in ...... ability in muscular dystrophy.
@en
Loss of positive allosteric in ...... ability in muscular dystrophy.
@nl
P2093
P2860
P356
P1476
Loss of positive allosteric in ...... ability in muscular dystrophy.
@en
P2093
Chiara Rinaldi
James G Tidball
Kyu H Myung
Meredith Oltmann
Michelle Wehling-Henricks
P2860
P304
P356
10.1093/HMG/DDP288
P577
2009-06-19T00:00:00Z